The Pharmacological Potential of Adenosine A _2A Receptor Antagonists for Treating Parkinson's Disease

TY - JOUR

T1 - The Pharmacological Potential of Adenosine A 2A Receptor Antagonists for Treating Parkinson's Disease

AU - Mori, Akihisa

AU - Chen, Jiang-Fan

AU - Uchida, Shinichi

AU - Durlach, Cecile

AU - King, Shelby M

AU - Jenner, Peter

N1 - Funding Information: Acknowledgments: Medical writing assistance (referencing and editing) was provided by Anita Chadha-Patel and Elizabeth Hocking of ACP Clinical Communications, Ltd. (Hertfordshire, UK) and funded by Kyowa Kirin, Inc. (Bedminster, NJ, USA). Publisher Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2022/4/6

Y1 - 2022/4/6

N2 - The adenosine A2A receptor subtype is recognized as a non-dopaminergic pharmacological target for the treatment of neurodegenerative disorders, notably Parkinson's disease (PD). The selective A2A receptor antagonist istradefylline is approved in the US and Japan as an adjunctive treatment to levodopa/decarboxylase inhibitors in adults with PD experiencing OFF episodes or a wearing-off phenomenon; however, the full potential of this drug class remains to be explored. In this article, we review the pharmacology of adenosine A2A receptor antagonists from the perspective of the treatment of both motor and non-motor symptoms of PD and their potential for disease modification.

AB - The adenosine A2A receptor subtype is recognized as a non-dopaminergic pharmacological target for the treatment of neurodegenerative disorders, notably Parkinson's disease (PD). The selective A2A receptor antagonist istradefylline is approved in the US and Japan as an adjunctive treatment to levodopa/decarboxylase inhibitors in adults with PD experiencing OFF episodes or a wearing-off phenomenon; however, the full potential of this drug class remains to be explored. In this article, we review the pharmacology of adenosine A2A receptor antagonists from the perspective of the treatment of both motor and non-motor symptoms of PD and their potential for disease modification.

KW - non-dopaminergic target

KW - Humans

KW - istradefylline

KW - Adenosine - pharmacology - therapeutic use

KW - A2A receptors

KW - adenosine

KW - Receptor, Adenosine A2A

KW - Adult

KW - Parkinson Disease - drug therapy

KW - Adenosine A2 Receptor Antagonists - pharmacology - therapeutic use

KW - Levodopa - therapeutic use

KW - G protein coupled receptor

KW - Parkinson’s disease

UR - http://www.scopus.com/inward/record.url?scp=85128027312&partnerID=8YFLogxK

U2 - 10.3390/molecules27072366

DO - 10.3390/molecules27072366

M3 - Article

C2 - 35408767

SN - 1420-3049

VL - 27

JO - Molecules (Basel, Switzerland)

JF - Molecules (Basel, Switzerland)

IS - 7

M1 - 2366

ER -